BRCA2 and breast carcinoma: Since brain metastases occur in approximately half the patients with advanced breast cancer with BRCA mutations [67], and BRCA2 mutation prevalence reached 22% in our meta-analysis, PARP inhibitors could be promising tools for the treatment of brain metastases.